Related Experiment Video
Updated: Jun 6, 2025

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
Published on: September 22, 2011
Effect of Salt Substitution on Cardiac Structure and ECG Parameters in Middle-aged and Elderly Hypertensive Patients
Li Che1, Ying Zhang2, Xia Chen3
1Department of Cardiology, Central Hospital of Dalian University of Technology, 116033 Dalian, Liaoning, China.
Insights
Salt substitution (SS) significantly improves cardiac structure and electrocardiogram (ECG) parameters in hypertensive patients. This intervention reduces left atrial diameter (LAD) and left ventricular mass (LVM), offering potential cardiac risk management benefits.
Area of Science:
- Cardiology
- Hypertension Management
- Cardiovascular Research
Background:
- Salt substitution (SS) is known to reduce blood pressure (BP).
- The effects of SS on cardiac structure and ECG parameters are not well understood.
- Hypertension poses significant cardiovascular risks.
Purpose of the Study:
- To evaluate the impact of salt substitution on cardiac structure using ultrasonic cardiogram (UCG).
- To assess the effects of salt substitution on electrocardiogram (ECG) parameters.
- To investigate the role of SS in managing cardiac risks in hypertensive individuals.
Main Methods:
- A 12-month, multi-center, randomized, double-blind study.
- Involved 352 hypertensive patients aged 50-70 years.
- Compared normal salt (NS) with salt substitution (SS) groups, measuring BP, UCG, and ECG parameters.
Main Results:
- Salt substitution significantly reduced systolic and diastolic BP compared to normal salt.
- SS led to significant reductions in left atrial diameter (LAD) and left ventricular mass (LVM).
- Improvements were observed in UCG parameters, including QT dispersion (QTd), Tp-e, and Tp-e/QT.
Conclusions:
- Salt substitution effectively improves cardiac structure (LAD, LVM) in hypertensive patients.
- SS positively impacts key ECG parameters (QTd, Tp-e, Tp-e/QT).
- SS represents a promising intervention for mitigating cardiac risks associated with hypertension.
Background:
Salt substitution (SS) has been found to reduce blood pressure (BP). However, the impact of SS on cardiac structure, as assessed through ultrasonic cardiogram (UCG) and electrocardiograms (ECG), remains poorly understood. This study aims to evaluate the effects of SS on cardiac structure and ECG parameters.
Methods:
This 12-month prospective, multi-center, randomized, double-blind study involved hypertensive patients aged 50 to 70 years with office systolic BP (SBP) ranging from 140 to 180 mmHg and diastolic BP (DBP) ranging from 90 to 110 mmHg. A total of 352 patients were enrolled and equally randomized to either the normal salt (NS) group or SS group. Office BP measurements (OBPM) were obtained at baseline and at 3, 6, and 12 months, while home BP measurements (HBPM) were recorded at baseline, 3, 6, 9, and 12 months. Fasting blood, UCG, and ECG parameters were obtained at baseline and at the end of the study.
Results:
Of the 352 enrolled patients, 322 completed the study. In the SS group, the reductions in systolic OBPM, HBPM, and diastolic HBPM were significantly greater than those in the NS group. Notable cardiac parameter changes included a reduction in QT dispersion (QTd) by -5 ms (-10, 5) in the NS group and -5 ms (-15, 0) in the SS group (p = 0.001); the T wave peak-to-end (Tp-e) value was 0 ms (-5, 10) and -5 ms (-10, 0) (p < 0.001), respectively; and Tp-e/QT was 0 (-0.01, 0.02) and -0.02 (-0.04, 0) (p < 0.001), respectively. Additionally, left atrial diameter (LAD) was 0 mm (-1, 1) and -1 mm (-2, 1) (p < 0.001), and the change in left ventricular mass (LVM) was -2 g (-17.75, 11) and -7 g (-18, 6) (p = 0.035), respectively.
Conclusions:
This study demonstrates that SS not only significantly decreased LAD and LVM, indicating a significant effect on cardiac structure, but also improves UCG parameters, including reductions in QTd, Tp-e, and Tp-e/QT. These findings highlight the potential of SS as a beneficial intervention in managing cardiac risks in hypertensive patients.
Clinical Trial Registration:
ChiCTR1800019727. (https://www.chictr.org.cn/showproj.html?proj=31036).
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Potassium-Sparing Diuretics
Mitral Regurgitation IV: Nursing Management

